Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus

Christopher L Shaffer, Peter Gal, J. Laurence Ransom, Rita Q. Carlos, McCrae S. Smith, Andrew M. Davey, M. A V T Dimaguila, Yvonne L. Brown, Stewart A. Schall

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Objectives: To determine patent ductus arteriosus (PDA) closure rates, and indomethacin (INDO) toxicity rates in neonates dosed with INDO using an individualized pharmacokinetic/pharmacodynamic (PK/PD) dosing approach. In addition, develop PD curves evaluating dose-response and concentration-response relationships for closure and renal toxicity, especially in select subgroups historically known as "poor responders" (<1000 g and ≥10 days postnatal age). Design: Prospective, cohort study. Setting: Level III neonatal intensive care unit. Subjects: One hundred thirty-nine patients receiving 151 courses of INDO for PDA closure were evaluated. Interventions: Patients initially received 0.25 mg/kg of INDO, followed immediately by 1 mg/kg of furosemide. INDO concentrations were obtained 2 hrs and 8 hrs after the dose and were assayed using high-performance liquid chromatography. Individualized PK parameters were calculated with subsequent INDO dosing based on the individualized PK variables to increase trough serum concentrations by 0.3-0.5 mg/L. Measurements and Main Results: Ductal closure was successful in 127 patients (91%). Renal toxicity occurred in 21 (15%) patients and was temporary and reversible. No significant differences in response rates based on treatment weight or postnatal age were observed. PD curves were similar for neonates <1000 g vs. ≥1000 g. PD curves were also similar for neonates with postnatal age <10 days vs. ≥10 days. Statistically significant differences were noted between neonates categorized for postnatal age <10 days vs. ≥ 10 days in total days of therapy (1.8 vs. 2.3 days), total number of doses required to close PDA (3.5 vs. 5.6 doses), critical INDO dose (0.9 vs. 1.4 mg/kg), critical INDO concentration (1.9 vs. 1.4 mg/L), and critical dose/critical concentration ratio (0.52 vs. 2.2). Conclusions: These findings support the hypothesis that the poor PDA closure rates with INDO for neonates >10 days postnatal age are the result of pharmacokinetic differences only and that weight does not impact response rates. Individualized pharmacokinetic/pharmacodynamic dosing of INDO continues to achieve higher closure rate than current dosing standards. Patients historically known as poor responders significantly benefit from this dosing approach.

Original languageEnglish (US)
Pages (from-to)343-348
Number of pages6
JournalCritical care medicine
Volume30
Issue number2
DOIs
StatePublished - Jan 1 2002

Fingerprint

Patent Ductus Arteriosus
Birth Weight
Indomethacin
Pharmacokinetics
Newborn Infant
Kidney
Weights and Measures

Keywords

  • Critical concentration
  • Indomethacin
  • Neonates
  • Patent ductus arteriosus
  • Pharmacodynamics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. / Shaffer, Christopher L; Gal, Peter; Laurence Ransom, J.; Carlos, Rita Q.; Smith, McCrae S.; Davey, Andrew M.; Dimaguila, M. A V T; Brown, Yvonne L.; Schall, Stewart A.

In: Critical care medicine, Vol. 30, No. 2, 01.01.2002, p. 343-348.

Research output: Contribution to journalArticle

Shaffer, CL, Gal, P, Laurence Ransom, J, Carlos, RQ, Smith, MS, Davey, AM, Dimaguila, MAVT, Brown, YL & Schall, SA 2002, 'Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus', Critical care medicine, vol. 30, no. 2, pp. 343-348. https://doi.org/10.1097/00003246-200202000-00013
Shaffer, Christopher L ; Gal, Peter ; Laurence Ransom, J. ; Carlos, Rita Q. ; Smith, McCrae S. ; Davey, Andrew M. ; Dimaguila, M. A V T ; Brown, Yvonne L. ; Schall, Stewart A. / Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. In: Critical care medicine. 2002 ; Vol. 30, No. 2. pp. 343-348.
@article{1ab70d1a623b43b1a1868c9ac7eb0fc1,
title = "Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus",
abstract = "Objectives: To determine patent ductus arteriosus (PDA) closure rates, and indomethacin (INDO) toxicity rates in neonates dosed with INDO using an individualized pharmacokinetic/pharmacodynamic (PK/PD) dosing approach. In addition, develop PD curves evaluating dose-response and concentration-response relationships for closure and renal toxicity, especially in select subgroups historically known as {"}poor responders{"} (<1000 g and ≥10 days postnatal age). Design: Prospective, cohort study. Setting: Level III neonatal intensive care unit. Subjects: One hundred thirty-nine patients receiving 151 courses of INDO for PDA closure were evaluated. Interventions: Patients initially received 0.25 mg/kg of INDO, followed immediately by 1 mg/kg of furosemide. INDO concentrations were obtained 2 hrs and 8 hrs after the dose and were assayed using high-performance liquid chromatography. Individualized PK parameters were calculated with subsequent INDO dosing based on the individualized PK variables to increase trough serum concentrations by 0.3-0.5 mg/L. Measurements and Main Results: Ductal closure was successful in 127 patients (91{\%}). Renal toxicity occurred in 21 (15{\%}) patients and was temporary and reversible. No significant differences in response rates based on treatment weight or postnatal age were observed. PD curves were similar for neonates <1000 g vs. ≥1000 g. PD curves were also similar for neonates with postnatal age <10 days vs. ≥10 days. Statistically significant differences were noted between neonates categorized for postnatal age <10 days vs. ≥ 10 days in total days of therapy (1.8 vs. 2.3 days), total number of doses required to close PDA (3.5 vs. 5.6 doses), critical INDO dose (0.9 vs. 1.4 mg/kg), critical INDO concentration (1.9 vs. 1.4 mg/L), and critical dose/critical concentration ratio (0.52 vs. 2.2). Conclusions: These findings support the hypothesis that the poor PDA closure rates with INDO for neonates >10 days postnatal age are the result of pharmacokinetic differences only and that weight does not impact response rates. Individualized pharmacokinetic/pharmacodynamic dosing of INDO continues to achieve higher closure rate than current dosing standards. Patients historically known as poor responders significantly benefit from this dosing approach.",
keywords = "Critical concentration, Indomethacin, Neonates, Patent ductus arteriosus, Pharmacodynamics, Pharmacokinetics",
author = "Shaffer, {Christopher L} and Peter Gal and {Laurence Ransom}, J. and Carlos, {Rita Q.} and Smith, {McCrae S.} and Davey, {Andrew M.} and Dimaguila, {M. A V T} and Brown, {Yvonne L.} and Schall, {Stewart A.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1097/00003246-200202000-00013",
language = "English (US)",
volume = "30",
pages = "343--348",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus

AU - Shaffer, Christopher L

AU - Gal, Peter

AU - Laurence Ransom, J.

AU - Carlos, Rita Q.

AU - Smith, McCrae S.

AU - Davey, Andrew M.

AU - Dimaguila, M. A V T

AU - Brown, Yvonne L.

AU - Schall, Stewart A.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Objectives: To determine patent ductus arteriosus (PDA) closure rates, and indomethacin (INDO) toxicity rates in neonates dosed with INDO using an individualized pharmacokinetic/pharmacodynamic (PK/PD) dosing approach. In addition, develop PD curves evaluating dose-response and concentration-response relationships for closure and renal toxicity, especially in select subgroups historically known as "poor responders" (<1000 g and ≥10 days postnatal age). Design: Prospective, cohort study. Setting: Level III neonatal intensive care unit. Subjects: One hundred thirty-nine patients receiving 151 courses of INDO for PDA closure were evaluated. Interventions: Patients initially received 0.25 mg/kg of INDO, followed immediately by 1 mg/kg of furosemide. INDO concentrations were obtained 2 hrs and 8 hrs after the dose and were assayed using high-performance liquid chromatography. Individualized PK parameters were calculated with subsequent INDO dosing based on the individualized PK variables to increase trough serum concentrations by 0.3-0.5 mg/L. Measurements and Main Results: Ductal closure was successful in 127 patients (91%). Renal toxicity occurred in 21 (15%) patients and was temporary and reversible. No significant differences in response rates based on treatment weight or postnatal age were observed. PD curves were similar for neonates <1000 g vs. ≥1000 g. PD curves were also similar for neonates with postnatal age <10 days vs. ≥10 days. Statistically significant differences were noted between neonates categorized for postnatal age <10 days vs. ≥ 10 days in total days of therapy (1.8 vs. 2.3 days), total number of doses required to close PDA (3.5 vs. 5.6 doses), critical INDO dose (0.9 vs. 1.4 mg/kg), critical INDO concentration (1.9 vs. 1.4 mg/L), and critical dose/critical concentration ratio (0.52 vs. 2.2). Conclusions: These findings support the hypothesis that the poor PDA closure rates with INDO for neonates >10 days postnatal age are the result of pharmacokinetic differences only and that weight does not impact response rates. Individualized pharmacokinetic/pharmacodynamic dosing of INDO continues to achieve higher closure rate than current dosing standards. Patients historically known as poor responders significantly benefit from this dosing approach.

AB - Objectives: To determine patent ductus arteriosus (PDA) closure rates, and indomethacin (INDO) toxicity rates in neonates dosed with INDO using an individualized pharmacokinetic/pharmacodynamic (PK/PD) dosing approach. In addition, develop PD curves evaluating dose-response and concentration-response relationships for closure and renal toxicity, especially in select subgroups historically known as "poor responders" (<1000 g and ≥10 days postnatal age). Design: Prospective, cohort study. Setting: Level III neonatal intensive care unit. Subjects: One hundred thirty-nine patients receiving 151 courses of INDO for PDA closure were evaluated. Interventions: Patients initially received 0.25 mg/kg of INDO, followed immediately by 1 mg/kg of furosemide. INDO concentrations were obtained 2 hrs and 8 hrs after the dose and were assayed using high-performance liquid chromatography. Individualized PK parameters were calculated with subsequent INDO dosing based on the individualized PK variables to increase trough serum concentrations by 0.3-0.5 mg/L. Measurements and Main Results: Ductal closure was successful in 127 patients (91%). Renal toxicity occurred in 21 (15%) patients and was temporary and reversible. No significant differences in response rates based on treatment weight or postnatal age were observed. PD curves were similar for neonates <1000 g vs. ≥1000 g. PD curves were also similar for neonates with postnatal age <10 days vs. ≥10 days. Statistically significant differences were noted between neonates categorized for postnatal age <10 days vs. ≥ 10 days in total days of therapy (1.8 vs. 2.3 days), total number of doses required to close PDA (3.5 vs. 5.6 doses), critical INDO dose (0.9 vs. 1.4 mg/kg), critical INDO concentration (1.9 vs. 1.4 mg/L), and critical dose/critical concentration ratio (0.52 vs. 2.2). Conclusions: These findings support the hypothesis that the poor PDA closure rates with INDO for neonates >10 days postnatal age are the result of pharmacokinetic differences only and that weight does not impact response rates. Individualized pharmacokinetic/pharmacodynamic dosing of INDO continues to achieve higher closure rate than current dosing standards. Patients historically known as poor responders significantly benefit from this dosing approach.

KW - Critical concentration

KW - Indomethacin

KW - Neonates

KW - Patent ductus arteriosus

KW - Pharmacodynamics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0036173269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036173269&partnerID=8YFLogxK

U2 - 10.1097/00003246-200202000-00013

DO - 10.1097/00003246-200202000-00013

M3 - Article

VL - 30

SP - 343

EP - 348

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 2

ER -